Premium
Molecular remission without blood product support using all‐ trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia
Author(s) -
Kennedy Glen A,
Marlton Paula,
Cobcroft Ralph,
Gill Devinder
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2000.02480.x
Subject(s) - arsenic trioxide , acute promyelocytic leukemia , retinoic acid , medicine , tretinoin , acute toxicity , toxicity , arsenic , pharmacology , immunology , chemistry , biochemistry , organic chemistry , gene
Arsenic trioxide has recently been used in the treatment of both relapsed and de novo acute promyelocytic leukaemia (APML). Molecular remissions have been attained using arsenic trioxide with minimal associated haematological toxicity, making protocols utilizing this drug an attractive option for Jehovah's Witnesses with APML. A 62‐year‐old female Jehovah's Witness with de novo APML was treated with all‐ trans retinoic acid induction followed by combined arsenic trioxide/ATRA consolidation, and achieved molecular remission with minimal haematological toxicity and no blood product support.